Collegium Pharma (COLL) Reports Q4 Loss of $1.02/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update
March 9, 2017 4:01 PM ESTXtampza® ER prescribed by more than 2,400 physicians since commercial launchONSOLIS® patent issued that extends patent protection until 2027Well capitalized with $153.2 million in cash and cash equivalents
CANTON, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the fourth quarter of 2016 and provided a corporate update.Â
We have made significant progress on the commercial launch of Xtampza ER. Through mid-February, more than 2,400 physicians have prescribed Xtampza ER, including 800 first time prescribers in 2017 alone, stated Michael Heffernan, Collegiums... More
